Direxion Daily S&P Biotech Bull 3X Shares

Key Statistics

Recent News

• LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout 24/7 Wall St.

  If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%. That is the pitch for

• Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now 24/7 Wall St.

  Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger activity pulled capital back into a sector that spent much of the

• Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026 24/7 Wall St.

  Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move

• Best-Performing Leveraged ETFs of October Zacks

  October's top ETF gainers included the likes of NVTX, AMUU, KORU, LABU and INTW. These ETFs soared as AI, crypto and reform optimism drove markets higher.

• Leveraged ETF Areas of Last Week That Are Up At least 15% Zacks

  Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.